Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Autor: Vincenza Conteduca, Jayaram, A., Romero-Laorden, N., Wetterskog, D., Salvi, S., Gurioli, G., Scarpi, E., Castro, E., Marin-Aguilera, M., Lolli, C., Schepisi, G., Maugeri, A., Wingate, A., Farolfi, A., Casadio, V., Medina, A., Puente, J., Vidal, Mjm, Morales-Barrera, R., Villa-Guzmán, Jc, Hernando, S., Rodriguez-Vida, A., González-Del-Alba, A., Mellado, B., Gonzalez-Billalabeitia, E., Olmos, D., Attard, G., Giorgi, U.

Publikováno v: European Urology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Università degli studi di Foggia-IRIS

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5a3b2d792bd066c01c1b2f901c9f01ab
http://europepmc.org/articles/PMC6377278

SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)

Autor: Valderrama, BP, Ramirez, SP, Rodriguez-Vida, A, del Alba, AG, Vidal, MJM, Estevez, SV, Ortega, EM, Virizuela, JA, Calvo, OF, Jorge, AH, Mazon, FJV, Gragera, MBG, Campayo, M, Ulazia, OE, Casado, EA, Moyano, MS, Villar, MTA, Rodriguez, CS, Diaz, EG, Arija, JAA

Publikováno v: Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::164dd466fb80c6a09c2ac19c4ee556e6
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3102

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Autor: Conteduca V; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. Electronic address: vincenza.conteduca@irst.emr.it., Jayaram A; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK; University College London Cancer Institute, London, UK., Romero-Laorden N; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain; Hospital Universitario La Princesa, Madrid, Spain., Wetterskog D; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; University College London Cancer Institute, London, UK., Salvi S; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Gurioli G; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Scarpi E; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Castro E; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain; Hospital Universitario Quirón, Madrid, Spain., Marin-Aguilera M; Department of Medical Oncology, IDIBAPS, Hospital Clínico y Provincial, Barcelona, Spain., Lolli C; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Schepisi G; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Maugeri A; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Wingate A; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; University College London Cancer Institute, London, UK., Farolfi A; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Casadio V; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Medina A; Centro Oncológico de Galicia, A Coruña, Spain., Puente J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Vidal MJM; Hospital Reina Sofía, Córdoba, Spain., Morales-Barrera R; Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Villa-Guzmán JC; Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Hernando S; Fundación Hospital Alcorcón, Alcorcón, Spain., Rodriguez-Vida A; Hospital del Mar, Barcelona, Spain., González-Del-Alba A; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Mellado B; Department of Medical Oncology, IDIBAPS, Hospital Clínico y Provincial, Barcelona, Spain., Gonzalez-Billalabeitia E; Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia, Spain; Universidad Católica San Antonio de Murcia-UCAM, Murcia, Spain., Olmos D; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain; CNIO-IBIMA Genitourinary Cancer Research Unit, Hospitales Universitario, virgen de la Victoria y regional de Málaga, Spain., Attard G; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK; University College London Cancer Institute, London, UK. Electronic address: g.attard@ucl.ac.uk., De Giorgi U; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Publikováno v: European urology [Eur Urol] 2019 Mar; Vol. 75 (3), pp. 368-373. Date of Electronic Publication: 2018 Oct 26.